Sarepta Therapeutics’ (SRPT) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research note published on Wednesday,Benzinga reports. They currently have a $75.00 price objective on the biotechnology company’s stock. Several other research analysts have also recently weighed in on SRPT. Morgan Stanley dropped their price objective on shares of […]